av Kim Larsen | jun 29, 2020
Business opportunity Inventors at the University of Oslo/Oslo University Hospital have developed an engineered human albumin variant with extended in vivo half-life. This unique albumin can be used as a fusion partner to improve the pharmacokinetics of...
av Kim Larsen | jun 29, 2020
Business opportunity Inventors at the University of Oslo/Oslo University Hospital have developed a novel technology for enhanced uptake of subunit vaccines across mucosal barriers. This technology is built on an engineered human albumin variant with increased mucosal...
av Kim Larsen | jun 29, 2020
Business opportunity Inventors at the University of Oslo/Oslo University hospital have developed a unique and versatile antibody Fc technology platform (“REW”). The technology increases the serum half-life and biodistribution properties of IgG antibodies and Fc...
